, /PRNewswire/ -- Researchers at (CHOP) announced the discovery of a novel immune-based biomarker that could pave the way for potential lifesaving early detection of high-grade ovarian cancer (HGOC). The findings were published today in the journal . High-grade ovarian cancer (HGOC) is the fifth-leading cause of cancer-related death among women.
More than 90% of women are diagnosed when the disease has reached advanced stages and has already spread, presenting significant treatment challenges. Ovarian cancer is highly treatable when caught early, but tests that look for conventional biomarkers haven't been able to detect microscopic, metastatic early lesions that often develop in the fallopian tubes. However, with the discovery of a novel immune-based biomarker, there is potential to change the trajectory for many women.
Although CHOP is a pediatric environment, its comprehensive is dedicated to improving children's lives and helping them thrive into adulthood through transformative solutions, such as new diagnostic tools, medicines, technologies, and policy recommendations. By tackling the most pressing healthcare challenges, CHOP dramatically advances wellness beyond pediatrics across the entire lifespan. "Early detection of ovarian cancer could mean the difference between life and death for millions of women," said , PhD, a core faculty member in the at Children's Hospital of .
"We believe our findings can be a gamechanger, providing insights for the development of an immu.